Ginkgo Bioworks Holdings logo

Ginkgo Bioworks HoldingsNYSE: DNA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 April 2021

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$424.04 M
-98%vs. 3y high
63%vs. sector
-vs. 3y high
-vs. sector
-96%vs. 3y high
28%vs. sector
-98%vs. 3y high
40%vs. sector

Price

after hours | 68 min ago
$7.63-$0.27(-3.42%)

Dividend

No data over the past 3 years
$56.21 M$45.00 M
$56.21 M-$217.18 M

Analysts recommendations

Institutional Ownership

DNA Latest News

Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
zacks.com04 November 2024 Sentiment: -

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.

DNA & RNA Banking Services Market Report 2024-2030, Featuring EasyDNA, DNA Genotek, 23andMe, GoodCell, ProteoGenex, Infinity Biologix, deCODE genetics, LGC Biosearch Technologies & PreventionGenetics
globenewswire.com28 October 2024 Sentiment: POSITIVE

Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "DNA & RNA Banking Services Market Size, Share and Trends Analysis Report by Service, Specimen (Blood, Buccal Swabs & Hair Follicles, Others), Application, End-use 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030.

Modifi Biosciences Acquired by Merck
globenewswire.com23 October 2024 Sentiment: POSITIVE

Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers

Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
accesswire.com15 October 2024 Sentiment: POSITIVE

STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.

KBRA Assigns Preliminary Ratings to Freddie Mac's STACR 2024-DNA3
businesswire.com03 October 2024 Sentiment: POSITIVE

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 24 classes from Freddie Mac Structured Agency Credit Risk (STACR®) REMIC 2024-DNA3 Notes, Freddie Mac STACR REMIC Trust 2024-DNA3 (STACR 2024-DNA3), a credit risk sharing transaction with a total note offering of $642,500,000. STACR 2024-DNA3 features loans with loan-to-value (LTV) ratios greater than 60%, but less than or equal to 80%. The Offered Notes represent obligations of the STACR 2024-DNA3 Trust in a credit-linked note stru.

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade
zacks.com26 September 2024 Sentiment: NEUTRAL

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.70, moving -0.77% from the previous trading session.

PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples
globenewswire.com25 September 2024 Sentiment: POSITIVE

PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA // Cell-free DNA in urine can provide important information to data not found in blood samples PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA // Cell-free DNA in urine can provide important information to data not found in blood samples

Pomerantz LLP Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA
globenewswire.com18 September 2024 Sentiment: NEUTRAL

OAKLAND, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA):

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology
prnewswire.com18 September 2024 Sentiment: POSITIVE

BOSTON , Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient.

Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today
fool.com17 September 2024 Sentiment: POSITIVE

The biotech rolled out two new healthtech innovations. One is a large language model (LLM) developed with its partner Alphabet.

What type of business is Ginkgo Bioworks Holdings?

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

What sector is Ginkgo Bioworks Holdings in?

Ginkgo Bioworks Holdings is in the Healthcare sector

What industry is Ginkgo Bioworks Holdings in?

Ginkgo Bioworks Holdings is in the Biotechnology industry

What country is Ginkgo Bioworks Holdings from?

Ginkgo Bioworks Holdings is headquartered in United States

When did Ginkgo Bioworks Holdings go public?

Ginkgo Bioworks Holdings initial public offering (IPO) was on 19 April 2021

What is Ginkgo Bioworks Holdings website?

https://www.ginkgobioworks.com

Is Ginkgo Bioworks Holdings in the S&P 500?

No, Ginkgo Bioworks Holdings is not included in the S&P 500 index

Is Ginkgo Bioworks Holdings in the NASDAQ 100?

No, Ginkgo Bioworks Holdings is not included in the NASDAQ 100 index

Is Ginkgo Bioworks Holdings in the Dow Jones?

No, Ginkgo Bioworks Holdings is not included in the Dow Jones index

When was Ginkgo Bioworks Holdings the previous earnings report?

No data

When does Ginkgo Bioworks Holdings earnings report?

The next expected earnings date for Ginkgo Bioworks Holdings is 08 November 2024